Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Research from West Virginia University has provided new information about breast cancer
September 18th, 2008
"Along with various imaging modalities, serologic tumor markers such as CA 15-3 and CA 27.29 have been used for decades to monitor treatment response in patients with metastatic breast cancer (MBC). Despite the frequent use of these markers, they lack high sensitivity and specificity for breast cancer progression," scientists in the United States report. "The prognostic significance of these markers remains indeterminate because of the conflicting outcome of many clinical trials: The circulating tumor cell (CTC) test has recently been studied in clinical trials in patients with MBC Some of the studies showed that high levels of CTCs are correlated with poor survival in...
Source: Women's Health Weekly (2008-09-18)
|
